FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Kraken Parent Acquires Bitnomial for $550M, Strengthening Crypto Offerings

This acquisition marks a significant expansion into derivatives trading.Highlights: Kraken's parent company announces $550M acquisition of Bitnomial.Bitnomial is...
FinTech

NatWest Group Strengthens Free Investment Guidance Programme

New initiative aims to educate more customers on investing.Highlights: NatWest Group expands free investment guidance programme.Initiative targets educating...
FinTech

Tether Launches New Stablecoin Wallet to Enhance User Experience

This innovative platform aims to improve accessibility for crypto users.Highlights: Tether has introduced a new stablecoin wallet.The wallet...
FinTech

FCA Strengthens Money Laundering Combat with Synthetic Dataset

New collaboration aims to enhance detection capabilities against financial crime.Highlights: FCA partners with Turing Institute to combat money...